July 10, 2025

Apheresis Shows Promise for Removing Microplastics From Human Blood

Extracorporeal therapeutic apheresis demonstrated the ability to remove microplastic-like particles from human blood in patients with myalgic encephalomyelitis/chronic fatigue syndrome, according to a study published in Brain Medicine.

Conexiant

July 10, 2025

1 in 4 US Infants Missing Bifidobacterium: Study

Babies who lacked this key gut bacteria were at an increased risk of eczema, allergies, and asthma by age 2.

Conexiant

July 09, 2025

Recombinant Zoster Vaccine Linked to New-Onset Lupus

Researchers report the first documented case of systemic lupus erythematosus following Shingrix vaccination.

Conexiant

July 07, 2025

FDA Approves First Oral Hereditary Angioedema Treatment

FDA approves Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema, shown in trials to provide faster symptom relief and eliminate the need for injection.

Conexiant

July 01, 2025

FDA Approves Low-IgA IG Therapy

GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.

Conexiant

June 24, 2025

AI vs. MDs: Who Navigates the Airways Better?

A new systematic review evaluated 20 studies on artificial intelligence in bronchoscopy and found AI systems often performed as well as or better than human experts in tasks such as airway navigation and lymph node classification.

Conexiant

June 23, 2025

Remote and Ready: Rethinking COPD Care

A large meta-analysis of 33 trials found that community-based COPD management models improved lung function, exercise capacity, and symptom control compared to usual care, though quality-of-life gains were not significant.

Conexiant

June 18, 2025

Cracking the Code of Phages to Fight TB

How new structural insights captured in high-resolution images could fuel next-gen therapies for TB

The Analytical Scientist

June 17, 2025

FDA-Approved Sweetener Found in Vapes

New laboratory analysis found widespread use of neotame, a potent artificial sweetener, in most disposable e-cigarettes sold in the United States, including nicotine-free and nicotine-analogue products.

Conexiant